[Sjögren's syndrome with autonomic failure and epilepsy].
BACKGROUND
Primary Sjogren syndrome is considered as the most frequent connective tissue disease. Neurological complications may affect the peripheral nervous system and to lesser extent the central nervous system. Autonomic system nervous dysfunction and epilepsy have been rarely reported.


METHODS
We present on case of Sjogren's syndrome with epilepsy and autonomic nervous system dysfunction. The epilepsia respond to valproate.


CONCLUSIONS
Autoimmune investigations for Sjogren's syndrome should be initiated in any patient presenting with unexplained neurologic manifestations.
Attout
H
H
Service de médecine interne, CHU Pellegrin, 33000 Bordeaux, France. hassene.attout@chu-bordeaux.fr
Martre
A
A
Guez
S
S
Series
C
C
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use; D001342:Autonomic Nervous System Diseases / Q000175:diagnosis / Q000209:etiology*; D004576:Electromyography; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D005438:Fludrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008879:Midodrine / Q000008:administration & dosage / Q000627:therapeutic use; D011115:Polyneuropathies / Q000175:diagnosis / Q000209:etiology*; D012859:Sjogren's Syndrome / Q000150:complications* / Q000175:diagnosis; D013566:Sympathomimetics / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D013566:Sympathomimetics; D014635:Valproic Acid; D008879:Midodrine; D005438:Fludrocortisone